Galecto

Galecto, Inc. is a clinical-stage biotechnology company focused on developing small molecules for the treatment of severe diseases, particularly fibrosis and cancer. Established in 2011, the company leverages over a decade of research into galectin-3 and LOXL-2, proteins that play crucial roles in fibrosis-related conditions. Galecto's therapeutic approach includes the development of small-molecule inhibitors, with primary candidates such as GB0139, aimed at treating idiopathic pulmonary fibrosis, and GB1211, a selective oral galectin-3 inhibitor targeting fibrosis associated with non-alcoholic steatohepatitis. The company possesses a strong patent portfolio, providing it with a distinctive platform for advancing treatments in these challenging medical areas.